OncoMatch/Clinical Trials/NCT06708897
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
Is NCT06708897 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ZE 50-0134 for cll / sll.
Treatment: ZE 50-0134 — This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grad lymphomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Excluded: TP53 deletion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BTK inhibitor
have received ≥2 prior therapies that have included a BTKi
Must have received: BCL2 inhibitor (venetoclax)
have received ≥2 prior therapies that have included a BTKi and venetoclax (or declined this)
Must have received: CD20 antibody-based therapy
received at least 2 therapies including a BTKi and CD20 antibody-based therapy
Cannot have received: BCL2 inhibitor (venetoclax)
No prior venetoclax treatment (FOR PART 2 ONLY)
Lab requirements
Blood counts
ANC > 0.75 x 10^9/L (or ≥ 0.5 x 10^9/L with bone marrow involvement); Platelet count > 50 x 10^9/L (or ≥ 30 x 10^9/L with bone marrow involvement)
Kidney function
Creatinine or Cystatin C GFR ≥60 mL/min
Liver function
AST/SGOT or ALT/SGPT ≤ 3.0 x ULN; Total bilirubin ≤ 1.5 x ULN
Adequate bone marrow, liver, and renal functions as assessed by the following laboratory requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Norton Cancer Institute, St. Matthews Campus · Louisville, Kentucky
- University of North Carolina at Chapel Hill · Chapel Hill, North Carolina
- University of Cincinnati · Cincinnati, Ohio
- The Ohio State University · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify